《現(xiàn)代脂質(zhì)三聯(lián)治療》ppt課件-文庫吧
2025-01-01 11:38 本頁面
【正文】 45 25 LDL Cholesterol (mg/dL) 0 2 4 6 8 10 12 14 16 LDL=5 LDL5 HDL= HDL LDL/HDL=5 LDL/HDL5 Incidence of cardiac events (per 1000 personyears) Gemfibrozil Placebo LDLC Tertiles (mmol/L) HDLC Tertiles (mmol/L) LDLC/HDLC Tertiles 24 46 32 36 34 45 22 39 38 53 18 29 Incidence for cardiac events vs lipid parameter Helsinki Heart Study MANNINEN V, Leena T, Koskinen P et al. Circulation 1992。 85: 3745 AFCAPS/TEXCAPS Apo B/A1 Tertiles LDLC/HDLC Tertiles 1 0 1 0 Event Rate per 100 PatientYears of Risk Event Rate per 100 PatientYears of Risk ? ? ? ??.4101 GOTTO A et al. Circulation 2022。 101: 477484 LDL/HDL Ratio as Therapeutic Success Placebo Statin 24 116 31 245 0 50 100 150 200 250 300 = 5 5 LDL / HDL Ratio Triglycerides 200 mg/dl Triglycerides = 200 mg/dl CAD cases per 1,000 subjects in 6 years ASSMANN G and SCHULTE H。 Am J Cardiol 1992。 70: 733737 Incidence of CAD vs LDL/HDL ratio by TG level (n = 4559) PROCAM Heart Study 0 50 100 150 200 250 300 3 4 5 5 6 7 LDL/HDL ratio CHD Incidence/1000 in 6 years CHD risk according to LDL/HDL ratio at baseline ASSMANN G。 Lipid Metabolism Disorders and CHD。 MMV Medizin Verlag, 1993: 43 5 High CHD risk Medium CHD risk Low CHD risk 35 3 PROCAM Heart Study Mean values for developing atherosclerotic CHD within 6 years Variable CHD Development No CHD Development (n = 186) (n = 4221) TC (mg/dl) HDLC (mg/dl) LDLC (mg/dl) LDL/HDL ratio TG (mg/dl) ASSMANN G。 Lipid Metabolism Disorders and CHD。 MMV Medizin Verlag, 1993: 41 PROCAM Heart Study Predictive value of risk factors for developing atherosclerotic CHD within 6 years Variable Risk Ratio Predictive Power % TG ? 200 mg/dl TC ? 250 (mg/dl) LDLC ? 195 (mg/dl) LDLC ? 155 (mg/dl) HDLC ? 35 (mg/dl) LDL/HDL ratio ? 5 ASSMANN G。 Lipid Metabolism Disorders and CHD。 MMV Medizin Verlag, 1993: 43 PROC
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1